A carregar...
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
OBJECTIVE: The use of alemtuzumab, a humanized monoclonal anti-CD52 antibody has changed the therapy of highly active relapsing-remitting MS (RRMS). Alemtuzumab infusion depletes most lymphocytes in peripheral blood, whereas differential recovery of immune cells, probably those with a less CNS-autor...
Na minha lista:
| Publicado no: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007635/ https://ncbi.nlm.nih.gov/pubmed/31826986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000654 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|